We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00168519
First Posted: September 15, 2005
Last Update Posted: December 15, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Information provided by:
Baker Heart Research Institute
  Purpose
The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.

Condition Intervention
Diabetes Mellitus, Type 2 Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Baker Heart Research Institute:

Primary Outcome Measures:
  • glucose metabolism [ Time Frame: 3 hours ]

Estimated Enrollment: 40
Study Start Date: October 2002
Study Completion Date: April 2009
Arms Assigned Interventions
Active Comparator: 1 Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Sodium Nitroprusside - one 30 minute intravenous infusion

Pentalong - two tablets orally (total 160mg)

Imdur - two tablets orally (total 120mg)


  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patients with type 2 diabetes

  • Non-smokers
  • Free of overt coronary disease (stress ECG)
  • Body mass index < 35 kg.m-2
  • Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
  • Unmedicated (diet controlled)

Healthy controls

  • Non-smokers
  • Free of overt coronary disease (ECG)
  • Body mass index < 30 kg.m-2
  • Fasting plasma glucose < 6.1 mmol.L-1
  • Unmedicated
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168519


Locations
Australia, Victoria
Baker Heart Research Institute
Melbourne, Victoria, Australia, 8008
Sponsors and Collaborators
Baker Heart Research Institute
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

ClinicalTrials.gov Identifier: NCT00168519     History of Changes
Other Study ID Numbers: 51/02
First Submitted: September 14, 2005
First Posted: September 15, 2005
Last Update Posted: December 15, 2009
Last Verified: December 2009

Keywords provided by Baker Heart Research Institute:
Diabetes Mellitus, Type 2
Blood Glucose
Exercise
Muscle Contraction
Nitric Oxide
Nitrates

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Nitroprusside
Antihypertensive Agents
Vasodilator Agents
Nitric Oxide Donors
Molecular Mechanisms of Pharmacological Action